MSN Labs launches branded generic of Cabozantinib for treatment of renal cell carcinoma
The company said its new division will focus on presenting a comprehensive range of affordable, high quality, bioequivalent generic oncology medicines benefiting patients in India.
Hyderabad: Hyderabad-based MSN Labs unveiled its new and dedicated oncology division- ‘Oncology Original Medicine’ by launching Cabolong, India’s first branded generic of Cabozantinib for treatment of renal cell carcinoma, a kidney cancer.
The company said its new division will focus on presenting a comprehensive range of affordable, high quality, bioequivalent generic oncology medicines benefiting patients in India. This move comes at a time wherein the cancer cases in the country are likely to increase to 15.6 lakhs by 2025, a 12 per cent increase from current estimated cases, based on current trends, according to the National Cancer Registry Programme Report 2020.
Cabolong, available in 20mg/40mg/60mg strengths at a price below Rs 10,000 for monthly treatment regimen will benefit Indian patients. The same therapy presently runs into lakhs with imported brands currently available in the market, the company stated.
Cabolong is manufactured at MSN Labs’ facility at Kothur, Hyderabad, approved by stringent global regulatory authorities such as the US FDA and EU GMP. The company has a presence in therapeutic segments such as cardiology, diabetology, pain, central nervous system, urology and gastroenterology, etc.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter.
